MEDICINAL AGENT (EMBODIMENTS) AND DEVICE FOR USING SAME

Abstract

The inventions are intended for stopping or slowing the progression of the acute phase of ischemic stroke, coronary failure and respiratory failure, and for saving injured and wounded persons suffering from heavy blood loss. A medicinal agent according to a first embodiment contains from 40 to 50 vol % helium, from 25 to 35 vol % argon, from 0.2 to 5 vol % xenon, from 2 to 10 vol % krypton, and not less than 21 vol % oxygen, to a total of 100 vol %, and the temperature of the gas mixture is 30-70 C. A medicinal agent according to a second embodiment contains from 21 to 60 vol % oxygen, from 0.2 to 35 vol % xenon, from 0.2 to 35 vol % krypton, or from 21 to 60 vol % oxygen, xenon in a concentration range of from 0.2 to 35 vol %, from 0.2 to 35 vol % krypton, and the remainder argon in an amount of not less 25 vol %, and the temperature of the gas is 15-70 C. The claimed device is characterized by a mask 1 connected to a breathing bag 7 and to a canister 12 containing an argon-xenon-krypton gas mixture, with a three-way valve for alternately supplying gases to the breathing bag 7, the device being further equipped with a canister 9 containing a helium-oxygen-argon-xenon-krypton gas mixture and having a valve mounted thereon with a manometer that is connected to the mask to permit a supply of the gas mixture directly into the mask 1, and a chemical or electric heater 11 with a connecting heat exchange line.

Claims

1. A medicinal product for maintaining the life of a person with severe blood loss, acute cerebral and myocardial ischemia, acute respiratory failure, and hypothermia, is the product comprising a mixture of gases comprising oxygen, xenon and argon, wherein the mixture of gases contains helium in the concentration range from 40 to 50% by volume, argon in the concentration range from 25 to 35% by volume, xenon in the concentration range from 0.2 to 5% by volume, krypton in the concentration range from 2 to 10% by volume and oxygenat least 21% by volume, up to 100% by volume in total, the temperature of the gas mixture is 30-70 C.

2. A medicinal product for maintaining the life of a person with severe blood loss, acute cerebral and myocardial ischemia, acute respiratory failure, and hypothermia, is the product comprising: a mixture of gases comprising oxygen, xenon, argon, wherein the mixture of gases contains oxygen in the concentration range from 21% by volume to 60% by volume, xenon in the concentration range from 0.2 to 35% by volume, krypton in the concentration range from 0.2 to 35% by volume, argon the rest in a concentration of at least 25% by volume, and the gas temperature is 15-70 C.

3. A device for maintaining the life of a person with severe blood loss, acute cerebral and myocardial ischemia, acute respiratory failure, and hypothermia with the help of medicines according to claim 1 (in the form of respiratory mixtures of medical gases), characterized by the presence of a facial partmask 1 with a mouthpiece located in it, a connective node 2, breathing bag 7 with overpressure valve, a baga dispenser 8 connected to a switchable check valve block and a regeneration cartridge 6 connected to a connecting line with a breathing bag 7, a cylinder with argon-xenon-krypton with a mixture of gases 12 or two smaller cylinders with argon and xenon and krypton in the assembly and with a three-way valve for alternately supplying gases to the breathing bag 7 through the gas mixture supply regulator 14, through connecting lines 15 for supplying the mixture to the breathing bag 7, a wrist laptop computer 16 with a heart rate sensor and oxygen saturation blood, oxygen and xenon concentration sensor in the breathing bag 7, designed to monitor and control the condition of the wounded, which is also characterized by, that it is additionally equipped with a balloon 9 with a medicinal productheliuman oxygen-argon-xenon-krypton mixture of gases, with a valve and a pressure gauge mounted on it, connected via a connecting line 10 to the mask with the possibility of supplying a mixture of gases directly into the mask 1, a chemical or electric heating pad 11c with a heat exchange connecting line, a switchable check valve block 3 installed between the outlet of the connecting node of the mask and the regeneration cartridge 6 pneumatically connected to a dispenser bag 8 and an exhalation line to the outside, an oxygen concentration sensor and an argon-krypton-xenon mixture.

4. The device according to claim 3, characterized in that the mask, the connecting node, the switchable block of the check valve, a chemical heating pad with a heat exchange connecting line, a breathing bag, connecting lines through which a breathing mixture of gases is supplied to it, a metering bag with a check valve are provided with thermal insulation.

5. The device according to claim 3, characterized in that, for long-term maintenance of human life, it additionally includes a transparent plastic container with an airtight zipper and built-in gloves for placing the injured person in it entirely, a mask placed in it connected to a dispenser bag with the possibility of putting it on the wounded person to stimulate breathing, and a device with a regenerating substance, as well as a dispenser bag with switchable check valve and connecting line, a cylinder with a mixture of gases or two separate cylinders of a smaller capacity with argon and xenon in the assembly and with a three-way valve for alternating gas supply, a gas mixture supply regulator, a connecting line for feeding the mixture into a dispenser bag, while the device is additionally equipped with a cylinder with a helium-oxygen-argon-xenon-krypton mixture of gases installed on it is equipped with a valve and a pressure gauge connected through a heat exchange connecting line to the mask with the possibility of supplying a mixture of gases directly into the mask, a chemical heating pad with a heat exchange connecting line and an overpressure valve hermetically installed in the wall of a plastic container, as well as in a cylinder 12 with a mixture of argon-xenon-krypton gases.

6. The device according to claim 5, characterized in that a transparent plastic container is provided with thermal insulation entirely.

Description

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1

[0081] FIG. 1 The design of the device for the creation and use of the claimed medicines is shown in FIG. 1.

[0082] The device contains a mask 1 with a sub-mask and a mouthpiece, a connecting node 2 made in the form of a connecting tube with three outlets, a switchable block of a check valve 3, an exhaling outward line 4, connecting lines 5, a regenerative cartridge 6 (for example the one of RP-4P type with a starting briquette), a breathing bag 7 with an overpressure valve, a dispenser bag 8 with a check valve (may be the one of the Ambu type), a cylinder 9 of small volume (for example from 0.2 to 1 liter) with high pressure (for example, up to 30 MPa), with a valve and a pressure gauge mounted on it, filled with a helium-oxygen-argon-xenon-krypton mixture of gases, a heat exchange connecting line 10 made in the form of a heat exchanger, a chemical or electric heating pad with a battery 11, as well as a cylinder 12 with argon-xenon-krypton gas mixture of small volume (for example, from 0.2 to 1 liter), with high pressure (for example, up to 30 MPa), or several separate cylinders of smaller capacity with argon, xenon and krypton, or a mixture of xenon+krypton, assembled, equipped with valves and pressure gauges each. An assembly unit 13 with a three-way valve for supplying the gas mixture through the regulator 14 and a connecting line 15 to the breathing bag 7 is connected to the cylinder 12 (or to the cylinders in the assembly).

[0083] The Mask 1, connecting node 2, check valve block 3, connecting lines 5 and heat exchange connecting line 10, breathing bag 7, the dispenser bag 8 with a check valve are equipped with thermal insulation (not shown in the drawing).

[0084] In addition, in order to monitor and control the condition of the patient or the wounded, the device is equipped with a wrist laptop computer 16 with a sensor for heart rate (HR), blood oxygen saturation and temperature of the wounded, and a sensor 17 for the concentration of oxygen and a mixture of argon, xenon, krypton in the breathing bag 7. The device is placed in a packing bag (not shown in the drawing) and is equipped with a key, a stopper, and other accessories.

[0085] The device works as follows.

[0086] After the device is assembled, it is necessary to initiate a chemical or electric heating pad 11 in order to heat the heat exchange connecting line 10 and the breathing gas mixture in it to a temperature of 30-70 C., to open the valve for supplying the breathing gas mixture of the cylinder 9, to check its supply, to set the operating mode of the switchable check valve block 3 to line 4 after exhaling outwards; the mask 1 is put on the patient or injured person, the first mixture of gases is supplied for a given time (from 5 to 30 minutes or more) in order to relieve hypothermia. Before completing the gas supply, controlled by the clock and the pressure gauge readings on the cylinder 9, the regenerative cartridge 6 is initiated by means of using a starting briquette, while the breathing bag 7 is filled with oxygen from the regenerative cartridge 6 through the connecting line 5.

[0087] Then, the valve of the cylinder 12 with argon, xenon and krypton is opened, in this case, through the assembly block 13, the regulator 14 and the connecting line 15, an argon-xenon-krypton mixture enters the breathing bag 7, and an oxygen-argon-xenon-krypton mixture with residual nitrogen is formed in it, the composition of which is adjusted according to the readings of the oxygen concentration sensor 17 and the argon-xenon-krypton mixture and the readings of the pressure gauge on the cylinder 12. Then the operating mode of the switchable block of the check valve 3 is set to the connecting line 5 to supply exhaled air towards the regenerative cartridge, if necessary, the valve of the cylinder 9 is closed, the excess of the resulting oxygen-argon-xenon-krypton mixture, with residual nitrogen, is drained through the overpressure valve of the breathing bag 7, and the remaining mixture enters it at inhalation through the regenerative cartridge 6 and the dispenser bag 8 for breathing to the wounded, while, if necessary, using the dispenser bag 8, it is possible to provide him with forced breathing. Further, during exhalation, the mixture passes through the regenerative cartridge 6 into the breathing bag 7, being purified from carbon dioxide and water vapor and enriched with oxygen, and the chemical purification reactions are exothermic, which provides enough heat to heat the mixture in the breathing bag to a temperature of 15-70 C., and then, when inhaled The oxygen-argon-krypton-xenon mixture of gases passes through the regenerative cartridge 6 a second time, once again being purified, heated and enriched with oxygen, thereby closing the breathing cycle.

[0088] In the described breathing cycle, argon, krypton and xenon gases are not consumed and do not decrease from the respiratory mixture involved in the respiratory cycle, due to their inertia, but may gradually decrease due to leaks in the mask 1, which can be controlled by a specialized sensor 17, or by analyzing the condition of the wounded taking into account computer readings 16, or based on the experience of the rescuer, and adjusted by adding an argon-krypton-xenon mixture or argon and xenon (krypton) separately from the cylinders 12 into the breathing bag 7. In this case, the dosing of the argon-xenon-krypton mixture from the cylinder 12 through the assembly unit 13, the regulator 14 and the supply line 15 to the breathing bag 7 is carried out the required number of times with control by the pressure gauges of the cylinders 12 and the sensor 17 to achieve a predetermined ratio of oxygen and argon-krypton-xenon for the required period of time up to 6-8 hours.

[0089] It is also possible to change the ratios of gases by bleaching part of them through the Mask 1.

[0090] In case of difficulty in self-breathing, it is possible to force it with the help of a dispenser bag 8, by periodically pressing on it.

[0091] When the resource of the regenerative cartridge 6 is exhausted, it can be replaced with a new one. In addition, it is also possible to replace the cylinder 9 with a helium-oxygen-argon-xenon-krypton medical mixture of gases, cylinders 12 and a chemical heating pad or an electric heating pad battery 11, and the procedure for preparing for work and the algorithm of operation is repeated.

FIG. 2

[0092] FIG. 2 The another version of the device is shown in FIG. 2.

[0093] In another variant of the device shown in FIG. 2, instead of a regenerative cartridge 6 and a breathing bag 7, a flexible plastic transparent container 18 with an airtight zipper can be used, in which the patient or injured person is placed entirely and in which a device 19 with a regenerative substance and a chemical carbon dioxide absorber, as well as the Mask 1, which can be worn on the wounded person if necessary, a connecting node 2, the bagdispenser 8, cylinders 9 and 12 with breathing gas mixtures, regulator 14 for the supply of gas mixture, connecting lines 5 and 15, a wrist laptop computer 16 fixed on the arm of the wounded with a sensor for heart rate (HR), blood oxygen saturation and temperature of the wounded and a sensor 17 for the concentration of oxygen and an argon-krypton mixture-xenon. Gloves can be embedded in container 18 to allow manipulation of the wounded and devices placed in the container (gloves are not shown in the figure). The container 18 must be insulated entirely.

[0094] The gas mixture from the cylinder 9 is fed directly into the mask 1, and exhalation is performed into the container 18, and then the excess gas is removed through the overpressure valve 20. The second gas mixture is created directly in the container when the gas mixture is supplied from the cylinder 12. A switchable check valve block 3 is not required in this case. The device 19 with a regenerative substance and a chemical carbon dioxide absorber located in container 18 is activated immediately after placing the injured person in the container.

[0095] An example of the use of claimed medicines and devices in real conditions.

[0096] In case of an attack of ischemia, injury or injury in the field conditions, with acute ischemia, large blood loss and in a state of hypothermia, the following actions are performed: [0097] the wounded person is treated, if possible, with antiseptic and hemostatic agents and a bandage or tourniquet is applied to stop bleeding; [0098] if possible, an injection of an analgesic solution is made by means of using a syringe tube, a tablet preparation of antibiotics is given inside; [0099] fighting asphyxia; [0100] compensate for blood loss, if possible, by infusion of saline solution and other available means; [0101] assemble the claimed device, initiate a chemical or electric heating pad, put on a mask for a sick or injured person and supply a heated mixture of gases according to Option 1Hearoxxenkrypto gas the required time to recover from hypothermia and stabilize the pre-terminal state; [0102] before the end of the supply of the first respiratory mixture, a regenerative cartridge is initiated and the components forming the second respiratory mixtureargon, xenon and kryptonare added to the gas mixture obtained in the respiratory bag in the required amount to form the Aroxxenkrypto gas in an oxygen concentration of 21% by volume up to 60% by volume, xenon from 0.2 to 35% by volume, krypton from 0.2 to 35% by volume, argon the rest in a concentration of at least 25% by volume, and the gas temperature is 15-70 C. due to heating of the gas in the regenerative cartridge, which ensures the transfer of the patient's body to the effective mode providing oxygen to the most important organs, analgesia, psychoemotional stabilization, provides broncholytic and thrombolytic effects, stable pre-terminal condition;

[0103] The effect of the application of this invention consists in a significant reduction in the probability of death in ischemic attacks, massive blood loss, acute respiratory failure and combined hypothermia due to an increased likelihood of timely delivery of the patient or wounded to hospital conditions due to withdrawal from hypothermia and a significant extension of the time to maintain the patient or wounded in a viable state in the period of evacuation from field or home conditions.

DESCRIPTION OF IMPLEMENTATION OPTIONS

[0104] Confirmation of the possibility of achieving target effects in the implementation of the invention are the results of special studies carried out under the guidance and with the participation of the authors, which were planned and delivered in a targeted manner to 000 Research Institute of GEROPRO, AO ASM, Rostov State Medical University, St. Petersburg Institute of Nuclear Physics named after B. P. Konstantinov, Research Establishment Kurchatov Institute, Federal State Budgetary Institution Research Institute of Influenza named after A.A. Smorodintsev of the Ministry of Health of the Russian Federation, AO Scientific development and production center HOUSE OF PHARMACY with the participation of volunteers and laboratory animals,

[0105] The main results of the conducted research were the following facts:

[0106] Artificial gas mixtures (AGM) of the claimed formulations, including heated ones, supplied for breathing to laboratory animals (rats, rabbits, pigs), in which acute attacks of cerebral and myocardial ischemia, acute massive blood loss in combination with exogenous hypothermia were simulated, have greater clinical efficacy in terms of prolongation of life and recovery rate The physiological functions of experimental animals are higher than air mixtures with identical (normal or elevated) oxygen content at normal or elevated temperatures.

[0107] Artificial gas mixtures of the claimed compositions and physical properties do not have acute and delayed toxic properties and local irritant effect, which has been proven in experiments on various types of laboratory animals (rats, ferrets), including with repeated use of tested AGMs, and with the participation of volunteers.

[0108] The ranges of concentrations of the components of the mixture that provide a therapeutic effect were investigated and established, values were found that provide the maximum effect or optimal values of the concentrations of the components, taking into account the error of measurement, creation, dosing of the mixture, for the purpose of maintaining the life of patients with acute cerebral and myocardial ischemia, acute respiratory failure, wounded with massive blood loss and hypothermia, for example: [0109] as a result of the complex of works of the Argon research and development based on the results of research on laboratory animals (State Scientific Center Institute of Bio-Medical Problems of the Russian Academy of Sciences) and with the participation of volunteer testers (AO ASM), as well as according to foreign sources (Martens A., Ordies S., Vanaudenaerde V. M. et al. A porcine ex vivo lung perfusion model with maximal argon exposure to attenuate ischemiareperfusion injury//Med. Gas Res.2017.Vol. 7.P. 28-36, etc.) the range of efficiency of a mixture of argon with oxygen for argon with the greatest effect is 30-70% by volume; [0110] as a result of a complex of works at the Rostov State University Medical University, taking into account research, as well as literature data, based on the results of studies on laboratory animals and with the participation of volunteer testers, the effective concentrations were estimated helium in a mixture with oxygen, argon, xenon and krypton, with an argon concentration of at least 25% by volume and oxygen from 21% by volume, providing antihypothermic and antihypoxic effects. The helium content should be at least 40% by volume, the temperature of the mixture should be from 30 to 70 C., and the initial temperature of the mixture should preferably be at the lower value of the range of change with an increase to the upper value for about 5 minutes and further maintenance or gradual decrease to 30 C.; [0111] the content of xenon and krypton and their ratios in the mixture are determined by the need to ensure the choice of achieving a hypoalgesic (0.2-10% by volume) or analgesic effect (30-40% by volume) (State Register of Medicines. Xenon (Xenonum). Official publication: in 2 volumesM.: Medical Council, 2009.Vol. 2, part 1568 p.; part 2560 p.); [0112] the need to use krypton is due to its properties (Kussmaul A. R., The biological effect of krypton on animals and humans under high pressure conditions, dissertation for the degree of Candidate of Biological Sciences, Institute of Bio-Medical Problems of the Russian Academy of Sciences, Moscow, 2007.), as well as the following: [0113] the critical temperature of krypton is 209.35 K, which allows it to be used in temperate latitudes in winter in the field and at Arctic temperatures without the risk of condensation (xenon289.74 K); krypton, having a xenon-like effect, is 5-8 times cheaper. [0114] a large permissible total relative error in setting the parameters of the mixture, reaching 10%, is due to the need to simplify the design and operation in the field and, at the same time, in the effective ranges found, does not significantly affect the effect of using the claimed drugs at concentrations of components in the claimed ranges; [0115] due to the wide ranges of effective concentrations of the components of the mixture and the smooth change in the effects of their effects, it is possible to create a family of drugs and a family of devices to implement the method within the declared concentration ranges, or (and) instructions for doctors to regulate the composition of the supplied mixture (qualitative and quantitative), within the general framework of the proposed device
For example: [0116] the device for regions with hot and warm climates can be lightweight, implemented according to the scheme FIG. 1, with a reduced capacity of the cylinder with mixture 1, the absence of insulation, the use of xenon mixtures in full, if necessary, up to 35% by volume;
the device for regions with moderate climate: [0117] in summera lightweight version, implemented according to the scheme FIG. 1, with a reduced capacity of the cylinder with mixture 1, the absence of insulation, the use of xenon and krypton mixtures in full; [0118] in winterthe full version according to the scheme FIG. 2, with an increased capacity of the cylinder with mixture 1, insulation, use in mixtures of xenon and krypton in full or with a predominance of krypton; [0119] the device for regions with an Arctic climate is a complete version according to the scheme FIG. 2, with an increased set of chemical heaters and minimization of xenon in mixtures 1 and 2.

EXAMPLES

[0120] Modeling of the pathological process (acute ischemia, massive blood loss in combination with exogenous hypothermia) was carried out on 2 types of laboratory animals (rats and rabbits) after preliminary anesthesia. Acute myocardial ischemia in rats was modeled by ligation of coronary vessels. Acute cerebral ischemia in rats was modeled by focal ischemia caused by occlusion of the middle cerebral artery (OMCA). Acute cerebral ischemia in rabbits was modeled by ligation of both carotid arteries and subsequent blood sampling from one of the carotid arteries above the ligature in a volume of 40% of the circulating blood volume (approximately 4% of the rabbit's body weight). Massive acute blood loss in rats up to 50% of the volume of circulating blood was modeled by transcutaneous puncture of the heart, in rabbits40-45% of the volume of circulating bloodby puncture of the femoral artery from a soft tissue incision. Exogenous hypothermia in both cases was modeled by pouring cold water on the operated animal, drying it with a towel and then placing it in a cold chamber with a temperature of minus 30 C. for 10 minutes, preventing frostbite and freezing of the animal. Body temperature was controlled rectally.

[0121] After modeling, the animals were randomly sorted into a control or experimental group.

[0122] The individuals of the control group were placed in a chamber with air temperature of 20+2 C., and oxygen content of 23+2% by volume, 40+2% by volume and 58+2% by volume. [0123] 1 The individuals of the experimental group were first placed under a hood, under which a heated mixture of Hearoxxenkrypto gases with a helium content of 45-50% by volume for 5 minutes and 20 minutes, and further, the animals were moved to a chamber with a mixture of gases Aroxxenkrypto with an initial temperature from 40+2 C. to 60+2 C., and an oxygen content of 23+2% by volume, 40+2% by volume and 58+2% by volume, argon content 33+2% by volume, krypton2+1% by volume, xenon2+1% by volume and the rest is nitrogen.

[0124] The general condition, rectal temperature, and death of animals were observed and recorded. Remote monitoring (mortality assessment) of the animals continued for several days.

[0125] The survival and recovery of vital functions of rats (21 individuals in the experimental group) or rabbits (9 individuals in each group) were observed after modeling ischemia or acute massive blood loss on the background of hypothermia, evaluated in paired experimental and control groups.

[0126] As a result of experiments according to claim 1, it was obtained: [0127] in experiments on ischemia in rabbits, the survival rate during exposure to the gas of the claimed 2 composition for up to 4 hours was 100%, in the control group33%. After cessation of exposure to medicinal gas of the claimed composition 2, the survival rate in the experimental group was 77.8%. [0128] in experiments with modeling massive blood loss, survival in experimental groups of laboratory animals was significantly higher: rats18 out of 21 (87.5%), rabbits9 out of 9 (100%) than in control: rats5 out of 12 (58%), rabbits3 out of 8 (37.5%); [0129] the oxygen content in the gas mixture in the experimental groups did not significantly affect the survival of laboratory animals, unlike the control group, where 6 animals died at 23+2% by volume, 4 animals at 40+2% by volume and 3 animals at 58+2% by volume. [0130] 2 The individuals of the experimental group of rats were first placed under a hood, under which a heated mixture of gases was supplied according to Variant 1 of the invention with a helium content of 45-50% by volume for 5 minutes, and further, the animals were moved into a chamber with a mixture of gases according to Variant 2 of the invention with an initial temperature from 40+2 C. to 60+2 C., and an oxygen content of 40+2% by volume, krypton10+2% by volume, xenon2+1% by volume and argonthe rest (about 43-53% by volume).

[0131] Survival and recovery of vital functions of rats after acute massive blood loss on the background of hypothermia were observed. [0132] 3 The individuals of the experimental group of rats were first placed under a hood, under which a heated mixture of gases was supplied according to Variant 1 of the invention with a helium content of 45-50% by volume for 5 minutes, and further, the animals were moved into a chamber with a mixture of gases according to Variant 2 of the invention with an initial temperature from 40+2 C. to 60+2 C., and an oxygen content of 40+2% by volume, krypton18+2% by volume, xenon2+1% by volume and argonthe rest (about 35-45% by volume).

[0133] As a result of experiments according to paragraphs 2 and 3, the following was obtained: [0134] survival rates in groups of rats given a mixture containing 10+2% by volume of krypton and 18+2% by volume of krypton are the same. [0135] the recovery of functions in the experimental group of rats at a concentration of krypton in a mixture of 18+2% by volume occurs somewhat faster (about 1.2-1.3 times) than in the group of rats at a concentration of krypton in a mixture of 10+2% by volume. [0136] 4 The individuals of the experimental group of rats were first placed under a hood, under which a heated mixture of gases was supplied according to claim 1 of the claims with a helium content of 45-50% by volume for 10 minutes, and further, the animals were moved into a chamber with a mixture of gases according to claim 2 of the claims with an initial temperature from 20+2 C. to 40+2 C., and an oxygen content of 40+2% by volume, krypton2+1% by volume, xenon2+1% by volume and the rest is argon.

[0137] Survival and recovery of vital functions of rats after acute massive blood loss on the background of hypothermia were observed. [0138] 5 The individuals of the experimental group of rats were first placed under a hood, under which a heated mixture of gases was supplied according to claim 1 of the claims with a helium content of 45-50% by volume for 20 minutes, and further, the animals were moved into a chamber with a mixture of gases according to claim 2 of the claims with an initial temperature from 20+2 C. to 40+2 C., and an oxygen content of 40+2% by volume, krypton2+1% by volume, xenon2+1% by volume and the rest is argon.

[0139] Survival and recovery of vital functions of rats after acute massive blood loss on the background of hypothermia were observed.

[0140] As a result of experiments according to paragraphs 4 and 5, it was obtained: [0141] survival rates in the group of rats who were given 1 mixture for 10 minutes are better than survival rates in the group of rats who were given 1 mixture for 20 minutes, which may indicate that there is an optimum efficiency of procedures when applying a warming mixture and switching to a maintenance mixture 2.

INDUSTRIAL APPLICABILITY

[0142] The analysis of the result of numerous experimental studies involving animals and volunteers, including the examples given, allowed us to determine the optimal effective composition for the variants of the gases Hearoxxenkrypto and Aroxxenkrypto to maintain human life with severe blood loss, acute cerebral and myocardial ischemia, acute respiratory failure, and with hypothermia.

[0143] The general composition of the medical gases Hearoxxenkrypto and Aroxxenkrypto and examples of target variants of the compositions of the claimed medicinal gases due to the symptoms of the patient's condition and ambient temperature are shown in Table 1.

[0144] The pharmacokinetics and pharmacodynamics of the claimed medicinal medical gases, their breadth of action, make it possible to produce a wide range of drugs with targeted action and applicability parameters within the claimed ranges of effective concentrations or create effective gas mixtures required for the current condition of a particular patient within the claimed compositions on site using the claimed devices.

[0145] Table 1Examples of formulations of variants of the claimed medicinal products of mixtures of medical gases for maintaining human life with severe blood loss, acute cerebral and myocardial ischemia, acute respiratory failure, and hypothermia.

TABLE-US-00001 TABLE 1 Examples of formulations of variants of the claimed medicinal products of mixtures of medical gases for maintaining the life of a person with severe blood loss, acute cerebral and myocardial ischemia, acute respiratory failure, and hypothermia Con- The quantitative composition of ditional the medicine, % by volume. medicinal impurities, product Ex- amount, T, No. name amples He O.sub.2 Xe Kr Ar ppm C. Purpose Effect Conditions of use 1 Hearoxxen- 40-50 no 0.2-5 2-5 the <500 30-70 maintaining warming, storage at a krypto (45 more rest human life at antihypoxic, temperature above 5) than 21 25 the initial stage analgesic, 16 C., application of withdrawal bronchodilator, for a short period from of 5-30 minutes hypothermia, relief of hypoxia, with large blood loss, acute cerebral myocardial ischemia, acute respiratory failure, with hypothermia. Ex- 45 23 2 5 the warning, storage at a ample rest antihypoxic temperature above 1.1 25 combined 16 C., application analgesic, for a short period bronchodilator, of 5-30 minutes decrease in blood viscosity Ex- 40 23 2 5 the warning, storage at a ample rest antihypoxic temperature above 1.2 30 enhanced, 16 C., application combined for a short period analgesic, of 5-30 minutes bronchodilator, decrease in blood viscosity Ex- 40 25 5 5 the warning, storage at a ample rest antihypoxic temperature above 1.3 25 enhanced, 16 C., application analgesic for a short period enhanced, of 5-30 minutes bronchodilator, decrease in blood viscosity Ex- 50 22.8 0.2 2 the warming storage and ample rest enhanced, application at 1.4 25 antihypoxic ambient analgesic, temperatures from bronchodilator, minus 50 C. to decrease in plus 40 C, 5-30 blood viscosity. minutes 2 Aroxxen- 0 21-60 0.2-35 0.2-35 the <500 15-70 maintaining toxic analgesic, universal, storage krypto rest human life at cybernetic, at temperatures 25 the stage of broncholytic above 16 C., arresting an anxiolytic long-term attack before application delivery to the hospital Ex- 0 60 2 3 the antihypoxic universal, storage ample rest analgesic, and application at 2.1 35 bronchodilator, the temperature for adults, above 16 C. Ex- 0 40 2 28 the for adults with universal, storage ample rest severe injuries and application at 2.2 30 and seizures, the temperature antihypoxic above 16 C. is enhanced, recommended analgesic enhanced, bronchodilator, anxiolytic, anticoagulant. Ex- 0 40 0.2 29.8 the for adults with universal, storage ample rest severe injuries and application at 2.3 30 and seizures, the ambient antihypoxic temperature from enhanced, minus 50 C. to analgesic plus 40 C. enhanced, broncholytic, anxiolytic, attention- anticoagulant Ex- 0 30 35 5 the for adults in a storage and ample rest terminal state, application at the 2.4 30 antihypoxic temperature above enhanced, 16 C. analgesic enhanced, cybernetic, narcotic, broncholytic, anxiolytic. Ex- 0 30 0.2 5 the 20-40 for new-borns universal, storage ample rest and application at 2.5 >25 the temperature 25-64, above 16 C. is 8 recoommended (+N.sub.2) Ex- 0 21 9 35 the 15-70 for adults in a storage and ample rest state of pain application at the 2.6 35 shock, temperature above antihypoxic, 16 C. analgesic enhanced, cybernetic, broncholytic, anxiolytie, anticoagulant. Ex- 0 21 1 10 the for the stage of universal, storage ample rest seizure relief, and application at 2.7 68 preconditioning, the ambient rehabilitation, temperature from prevention, minus 50 C. to antihypoxic, plus 40 C. analgesic, broncholytic, anxiolytic. anticoagulant indicates data missing or illegible when filed